Skip to content

Abnormal Concentration Of Acylcarnitine In The Urine C5139564

Published: July 22, 2026Updated: August 20, 2026

A condition where certain fatty substances appear in abnormal amounts in urine. This may indicate metabolic or genetic disorders affecting how the body processes fats. Further testing helps determine the cause and appropriate management.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Cardiomyopathy

Disease of the heart muscle that can cause reduced pumping function and heart rhythm abnormalities.

Seek immediate care for chest pain, shortness of breath, palpitations, or fainting.

!

Seizures

Uncontrolled electrical activity in the brain causing convulsions, loss of consciousness, or unusual movements.

Seek immediate emergency care for any seizure lasting more than 5 minutes or if it's the first occurrence.

!

Metabolic crisis

Severe metabolic decompensation with confusion, lethargy, and rapid deterioration due to accumulated toxins.

Seek emergency care immediately for confusion, extreme lethargy, rapid worsening, or inability to stay awake.

!

Heart rhythm abnormalities

Irregular heartbeat or arrhythmias that may cause palpitations, dizziness, or fainting.

Seek immediate care for fainting, severe dizziness, chest pain, or feeling of irregular heartbeat.

Persistent fatigue

(constitutional)

Generalized tiredness and lack of energy that persists throughout the day, often worsened by physical activity.

Frequency: 70-80% of patients

Muscle weakness

(neurologic)

Reduced muscle strength, particularly in the arms and legs, making it difficult to perform usual activities.

Frequency: 65-75% of patients

Nausea and vomiting

(gastrointestinal)

Feeling of sickness with stomach discomfort followed by expulsion of stomach contents.

Frequency: 50-60% of patients

Hypoglycemia

(constitutional)

Low blood sugar levels causing shakiness, sweating, confusion, and hunger.

Frequency: 40-50% of patients

Abdominal pain

(gastrointestinal)

Discomfort or pain in the stomach area, often associated with digestive disturbance.

Frequency: 35-45% of patients

Liver dysfunction

(gastrointestinal)

Impaired liver function shown by elevated liver enzymes, jaundice, or poor metabolism of fats and proteins.

Frequency: 15-20% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

L-carnitine supplementation

Carnitine replacement therapy to address potential carnitine deficiency contributing to abnormal acylcarnitine excretion. Treatment requires regular monitoring of carnitine levels and adjustment based on metabolic response.

medication
3

Low-fat diet with complex carbohydrates

Dietary modification reducing fatty acid metabolism burden by limiting long-chain fat intake while emphasizing carbohydrate sources to support energy needs.

dietary

Additional treatment options

Medium-chain triglyceride (MCT) oil supplementation

MCTs provide alternative fuel source that bypasses carnitine-dependent metabolism, reducing metabolic stress on fatty acid oxidation pathways.

dietary

Avoidance of prolonged fasting

Regular meal timing and snack schedules prevent extended periods without caloric intake that could trigger metabolic decompensation.

lifestyle

Metabolic laboratory monitoring

Serial measurement of acylcarnitine profiles and metabolic markers to assess treatment efficacy and disease progression.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Abnormal Concentration Of Acylcarnitine In The Urine C5139564?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, Howell RR. Serving the family from birth to the end of follow-up: A two-generation approach to newborn screening and genetic services. Genetics in Medicine. 2022;24(3):515-530.

guideline2022View source →
2

Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genetics in Medicine. 2008;10(2):151-156.

review2008View source →
3

American College of Medical Genetics and Genomics. Newborn screening: Towards a uniform screening panel and system. Genetics in Medicine. 2006;8(Suppl 1):1S-252S.

guideline2006View source →
4

Kumar T, Kasahara J, Matern D, et al. Clinical practice guidelines for fatty acid oxidation disorders: Recommendations from the Society for Inherited Metabolic Disorders. Molecular Genetics and Metabolism. 2020;131(1-2):1-15.

position_statement2020View source →
5

Spiekerkoetter U, Lindner M, Santer R, et al. Treatment recommendations for long-chain fatty acid oxidation disorders: Consensus from a European multicenter study. Orphanet Journal of Rare Diseases. 2019;14(1):138.

clinical_trial2019View source →
6

Hoffmann GF, Kölker S. Organic acidemias and fatty acid oxidation disorders. In: Saudubray JM, van den Heuvel L, editors. Inborn Metabolic Diseases: Diagnosis and Treatment. 7th ed. Springer; 2022:345-380.

review2022
7

Miller MJ, Kennedy AD, Eckhart AD, et al. Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism. Journal of Inherited Metabolic Disease. 2015;38(6):1029-1039.

meta_analysis2015View source →
8

Elsas LJ, Rhead W, Marsden D, et al. Consensus clinical management guidelines for carnitine palmitoyltransferase 2 deficiency. Molecular Genetics and Metabolism. 2021;134(1-2):43-54.

consensus2021View source →

Medication Comparisons

Compare medications used to treat Abnormal Concentration Of Acylcarnitine In The Urine C5139564. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy